- March 15, 2022
- Newsletter
- 617-430-5616
Menu
Menu
Menu
Menu
Menu
Menu
Brand Name :
Ifex, Iphox, Fosfa
Synonyms :
Class :
Class: anti cancer drugs (antineoplastic agents), Sub class: nitrogen mustards
Dosage forms and strengths:
Injectable powdered form or solution:
Injectable solution:
Kit of powder with mesna solution
Adult:
A dose of 1.2 g per m2 IV given over at least 30min daily for about 5 consecutive days.
The treatment can be repeated every 3 weeks or after recovery from hematologic toxicity.
A dose of 5 g per m2 IV mixed with equal dose of mesna over 24 hours beginning on day 2, etoposide 100 mg per m2/day on days 1-3, carboplatin AUC 5 IV on day 2, every 2 weeks for 3 cycles, was developed to treat relapsed condition and allow for adequate stem cell collection prior to transplant.
A dose of 2.5 g per m2/day continuous IV infusion over 24hrs on days 1-5.
Epirubicin 45 mg per m2/day CIV on days 2 and 3 administered every 3 weeks with growth-factor support with filgrastim.
The dacarbazine dose of 250 mg per as a continuous IV infusion for 4 days and doxorubicin 15 mg per m2/day CIV for 4 days and ifosfamide 2000 mg per m2/day CIV for 3 days, and mesna 2000 mg per m2/day CIV for 4 days repeated every 21 days.
The dosage can be taken if needed but caution needs to be followed.
The dosage can be taken if needed but caution needs to be followed.
Dosage forms and strengths:
Injectable powdered form or solution:
Injectable solution:
Kit of powder with mesna solution
Pediatric:
For Adults less than or equal to 21 years, adolescents, and children a dose of carboplatin 635 mg per m2 IV on day 3 in combination with ifosfamide 3,000 mg per m2/day IV on days 3-5 and etoposide 100 mg per m2/day IV on days 3-5 repeated each cycle.
Rituximab a dose 375 mg per m2/day was given on day 1 and 3 of cycles 1 and 2, and on day 3 only of cycle 3.
A maximum of 3 cycles of treatment is recommended.
For Adults less than or equal to 21 years, adolescents, and children Ifosfamide a dose of 1800 mg per m2/day IV for 5 days and carboplatin 400 mg per m2/day IV for 2 days and etoposide 100 mg per m2/day IV for 5 days and this is repeated for every 21 days.
The dosage can be taken if needed but caution needs to be followed.
The dosage can be taken if needed but caution needs to be followed.
influenza virus vaccine quadrivalent
ifosfamide decreases the effect of action of influenza virus by antagonism.
ifosfamide decreases the effect of action of measles vaccine by antagonism.
ifosfamide decreases the effect of action of rubella vaccine by antagonism.
ifosfamide decreases the effect of action of rotavirus vaccine by antagonism.
ifosfamide decreases the effect of action of smallpox vaccine by antagonism.
ifosfamide decreases the effect of action of varicella virus vaccine by antagonism.
ifosfamide decreases the effect of action of yellow fever vaccine by antagonism.
ifosfamide decreases the effect of action of zoster vaccine by antagonism.
ifosfamide through pharmacodynamic antagonism, reduces the impact of the live rotavirus oral vaccine on the body
By immunosuppressive effects, the both the drugs action either decreases and results in risk of infection.
when both drugs combine the risk of nephrotoxicity and ototoxicity increases.
By immunosuppressive effects, the both the drugs action either decreases or results in risk of infection.
By immunosuppressive effects, the both the drugs action either decreases or results in risk of infection.
when both drugs combine the risk of both drug increases the toxicity of other by synergism.
when both drugs combine fexinidazole will increase effect of ifosfamide by affecting the enzyme CYP3A4 metabolism.
By immunosuppressive effects, the both the drugs action either decreases and results in risk of infection.
when both drugs combine lonafarnib will increase effect of ifosfamide by affecting the enzyme CYP3A4 metabolism.
By immunosuppressive effects, the both the drugs action either decreases and results in risk of infection.
By immunosuppressive effects, the both the drugs action either decreases and results in risk of infection.
By immunosuppressive effects, the both the drugs action either decreases and results in risk of infection.
By immunosuppressive effects, the both the drugs action either decreases and results in risk of infection.
By immunosuppressive effects, the both the drugs action either decreases and results in risk of infection.
CYP3A enhancers (strong) may increase plasma concentrations of the active metabolite(s) of ifosfamide enzal
when both drugs combine abiraterone will increase effect of ifosfamide by affecting the enzyme CYP3A4 metabolism.
when both drugs combine the risk of both drug increases the toxicity of other by synergism.
when both drugs combine amiodarone will increase effect of ifosfamide by affecting the enzyme CYP3A4 metabolism.
when both drugs combine atazanavir will increase effect of ifosfamide by affecting the enzyme CYP3A4 metabolism.
when both drugs combine atogepant will increase effect of ifosfamide by affecting the enzyme CYP3A4 metabolism.
when both drugs combine axitinib will increase effect of ifosfamide by affecting the enzyme CYP3A4 metabolism.
when both drugs combine the risk of both drug increases the toxicity of other by synergism.
By immunosuppressive effects, the both the drugs action either decreases and results in risk of infection.
when both drugs combine the risk of both drug increases the toxicity of other by synergism.
when both drugs combine bexarotene will increase effect of ifosfamide by affecting the enzyme CYP3A4 metabolism.
when both drugs combine bicalutamide will increase effect of ifosfamide by affecting the enzyme CYP3A4 metabolism.
when both drugs combine bosentan will increase effect of ifosfamide by affecting the enzyme CYP3A4 metabolism.
when both drugs combine brigatinib will increase effect of ifosfamide by affecting the enzyme CYP3A4 metabolism.
when both drugs combine the risk of both drug increases the toxicity of other by synergism.
when both drugs combine butabarbital will increase effect of ifosfamide by affecting the enzyme CYP3A4 metabolism.
when both drugs combine carbamazepine will increase the effect of ifosfamide by affecting the enzyme CYP3A4 metabolism.
when both drugs combine the risk of both drug increases the toxicity of other by synergism.
when both drugs combine the risk of both drug increases the toxicity of other by synergism.
when both drugs combine the risk of both drug increases the toxicity of other by synergism.
when both drugs combine cobicistat will increase effect of ifosfamide by affecting the enzyme CYP3A4 metabolism.
when both drugs combine conivaptan will increase the effect of ifosfamide by affecting the enzyme CYP3A4 metabolism.
when both drugs combine the risk of both drug increases the toxicity of other by synergism.
when both drugs combine dabrafenib will increase the effect of ifosfamide by affecting the enzyme CYP3A4 metabolism.
when both drugs combine the risk of both drug increases the toxicity of other by synergism.
By immunosuppressive effects, the both the drugs action either decreases and results in risk of infection.
when both drugs combine erythromycin base will increase the effect of ifosfamide by affecting the enzyme CYP3A4 metabolism.
when both drugs combine erythromycin base will increase the effect of ifosfamide by affecting the enzyme CYP3A4 metabolism.
when both drugs combine erythromycin lactobionate will increase the effect of ifosfamide by affecting the enzyme CYP3A4 metabolism.
when both drugs combine erythromycin stearate will increase the effect of ifosfamide by affecting the enzyme CYP3A4 metabolism.
when both drugs combine the risk of both drug increases the toxicity of other by synergism.
when both drugs combine amobarbital will increase effect of ifosfamide by affecting the enzyme CYP3A4 metabolism.
when both drugs combine armodafinil will increase effect of ifosfamide by affecting the enzyme CYP3A4 metabolism.
By immunosuppressive effects, the both the drugs action either decreases and results in risk of infection.
By immunosuppressive effects, the both the drugs action either decreases and results in risk of infection.
when both drugs combine belzutifan will increase effect of ifosfamide by affecting the enzyme CYP3A4 metabolism.
the effect of action increases by effecting enzyme CYP2B6 metabolism
when both drugs combine erythromycin acetate will increase the effect of ifosfamide by affecting the enzyme CYP3A4 metabolism.
May increase the anti-coagulant action when combined
it may diminish the excretion rate when combined with permethrin, resulting in an enhanced serum level
ifosfamide: they may diminish serum concentrations of CYP3A4 Inducers
ifosfamide: they may diminish serum concentrations of CYP3A4 Inducers
ifosfamide: they may diminish serum concentrations of CYP3A4 Inducers
ifosfamide: they may diminish serum concentrations of CYP3A4 Inducers
ifosfamide: they may diminish serum concentrations of CYP3A4 Inducers
By synergism effects, the toxicity of the other drug increases.
when both drugs are combined, there may be an increased metabolism of ifosfamide
when combined with ifosfamide, the metabolism of thiotepa increases
when both the drugs are combined, the risk or severity of adverse effects increases
when both drugs are combined, there may be an increased risk or severity of adverse effects
increases cardiac distress risk
when both drugs are combined, there may be an increased risk or severity of adverse effects
may enhance the risk of immunosuppression and bone marrow suppression
the effect of isofamide is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
CYP3A4 inhibitors decrease the concentration of active metabolites of ifosfamide in serum
increases cardiac distress risk
may enhance the serum concentration of CYP3A4 inhibitors
when both drugs combine ruxolitinib will increase the effect of ifosfamide by affecting the enzyme CYP3A4 metabolism.
when both drugs combine the effect of both drug increases by synergism.
Adverse drug reactions:
Frequency defined
0.5-0.5%
1.8-1.8%
Frequency not defined
Pregnancy and Lactation:
Pregnancy:
Lactation:
Pregnancy Categories:
Ifosfamide is an anti-cancer agent used to treat testicular cancer. It acts by retarding or cessing the growth of cancerous cells.
The dose is given intravenously under the supervision of a healthcare provider. The quantity depends upon the medical condition, age, and body weight.
You should not expose your skin to this drug. If it encounters skin, rinse and wash off with soap.
Take plenty of fluids during medication.
Side effects accompanying ifosfamide are nausea, diarrhea, vomiting, drowsiness, mouth ulcers, loss of appetite, abdominal pain, and constipation.
Immediately report any severe side effects to the doctor. It may include irregular heartbeat, sudden weight change, dysmenorrhea, blurred vision, dysuria, and seizure.
The product may cause allergic reactions.
The drug may cause dizziness; therefore, do not drive or use machinery to be safe on your end.
Avoid encountering people with previous infections like flu, chickenpox, and measles.
Do not take the medication if you are pregnant or planning to conceive. Lactating females should not breastfeed during the treatment.
The fertile males should use protection during a sexual activity during the treatment with ifosfamide.
Pregnant females should not take this medication, and if, in due course, a female gets pregnant, she should consult the doctor.
If you miss a dose, ask your physician to reschedule it.
Always be aware of the dosing schedule to maintain a perfect regime.
Consult the pharmacist for the storage details and keep them away from children and pets.
ADVERTISEMENT
